USAID Ukraine is in the process of designing the new “Resilient Systems for Transparent, Reliable, and Effective Pharmaceutical Governance” (RESTORE) Activity for implementation in Ukraine. We seek comments on the questions listed in Attachment A to inform the design process. Responses to this RFI are not binding on the U.S. Government and do not obligate USAID to issue a solicitation, nor does it commit USAID to pay any cost incurred in the preparation and submission of comments.

The overall goal of this proposed five-year program is to strengthen and align the pharmaceutical system in Ukraine to European Union norms and standards, enhancing transparency and cost-efficiency for desired health outcomes. This activity would support the ongoing efforts of the Government of Ukraine (GoU) and its civil society partners to transform its healthcare system to effectively meet the needs of its citizens. Specifically, it would provide technical assistance in support of the GoU, civil society, and the private sector to improve the public procurement, distribution, and availability of quality-assured medicines and health commodities. In addition, the activity would contribute to the creation of sustainable health pharmaceutical financing, strengthen both rational pharmaceutical management and the pharmaceutical supply chain, and support health system recovery and reform following Russia's full-scale invasion of Ukraine. 

Building on the achievements of the USAID-funded Safe, Affordable, and Effective Medicines for Ukrainians (SAFEMed) activity, this activity would offer state of the art technical solutions to further transparent pharmaceutical financing and procurement systems, as well as to optimize supply chain management practices. Implemented solutions would support decentralization and integration of health services across national and sub-national levels and secure a stable supply of medicines and medical devices, to include: commodities for the detection, treatment, and prevention of HIV, TB, Hepatitis, Syphilis, COVID-19 and other emergent threats; as well as other quality-assured essential medicines.